GSK appoints new sales and marketing heads in China; Mylan bids $9B+ for Sweden's Meda;

@FiercePharma: Top-read on FiercePharmaManufacturing Thurs: Hospira recalls 7 lots of propofol and one of lidocaine Story | Follow @FiercePharma

@TracyStaton: @Indianmarketeer: Novartis seems to think it can pump up sales of GSK's drugs better than GSK could. But as you say, time will tell. | Follow @TracyStaton

@EricPFierce: A large block of #AstraZeneca shareholders voted against the company's pay plan and one of its directors. More | Follow @EricPFierce

@CarlyHFierce: Arena - Television Ads Raise Awareness. Report from SeekingAlpha | Follow @CarlyHFierce

> GlaxoSmithKline ($GSK) has appointed two executives to new roles overseeing sales and marketing in China after authorities accused the firm of corruption last year, a person with direct knowledge of the decision told Reuters. Report

> Mylan ($MYL) has made a new bid for Sweden's Meda, this time at more than $9 billion. More

> The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion on GSK melanoma drug Mekinist. Release

> Prestige Brands has reached an agreement to buy Insight Pharmaceuticals for $750 million. Story (sub. req.)

> The FDA has approved a new plant for Strides Arcolab in Bangalore, where it will manufacture oral medicines. Story

> Celgene ($CELG) is paying Ireland's Nogra Pharma $710 million upfront to buy its late-stage product for Crohn's disease and other gastrointestinal disorders. Story

Medical Device News

@FierceMedDev: Stryker's sales jump after string of M&A deals. More | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Zimmer buying fellow orthopedics company Biomet for $13.35 billion. | Follow @VarunSaxena2

@EmilyWFierce: Security holes in a number of commonly used medical devices could leave them open to attack. Article | Follow @EmilyWFierce

@MichaelGFierce: ICYMI: DNA nanocages that act like viruses bypass the immune system to deliver drugs. Story | Follow @MichaelGFierce

> Roche's HPV test gets FDA approval for primary cervical cancer screen. More

> Ariosa tests the waters with plans for a $60M IPO. News

> Covidien quarterly sales up 3% to $2.6 billion. Article

Biotech News

@FierceBiotech: EuroBiotech Report: GlaxoSmithKline & Novartis reshape EU biotech, Celgene, Hyperion in Euro deals, U.K. cell therapy grows, and more. Report | Follow @FierceBiotech

@JohnCFierce: Pyott told me back in January he could easily spend $10 billion on buyouts. Though that's not Shire territory. Story from January | Follow @JohnCFierce

@DamianFierce: ICYMI: Celgene opens down 5%. Perhaps a $710M deal didn't thrill investors who just watched R&D costs drag profits. | Follow @DamianFierce

@EmilyMFierce: Blood of world's oldest woman hints at limits of life. More | Follow @EmilyMFierce

> Arch Venture swings for a $250M fund to bet on biotechs. Story

> Buyout buzz: Allergan made a pass at Shire before Valeant came calling. Article

> Radius dials up a $92M IPO pitch despite tepid market for biotechs. News

And Finally... The FDA has proposed its rules for e-cigarette regulation. More

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.